-
公开(公告)号：US20190092788A1
公开(公告)日：2019-03-28
申请号：US16141856
申请日：2018-09-25
Applicant: NOVARTIS AG
Inventor： Simone BONAZZI , Michael CONNOLLY , David Jonathan GLASS , Manuel MIHALIC , Andrew William PATTERSON , Silvio ROGGO , Tea SHAVLAKADZE
IPC: C07D498/18 , A61P35/00 , A61P13/12 , A61P1/16
Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
-
公开(公告)号：US20220242878A1
公开(公告)日：2022-08-04
申请号：US17499433
申请日：2021-10-12
Applicant: NOVARTIS AG
Inventor： Simone BONAZZI , Michael CONNOLLY , David Jonathan GLASS , Manuel MIHALIC , Andrew William PATTERSON , Silvio ROGGO , Tea SHAVLAKADZE
IPC: C07D498/18 , A61P1/16 , A61P13/12 , A61P35/00 , A61P25/16 , A61P37/00 , A61P9/10 , A61P19/10 , A61P19/00 , A61P29/00 , A61P31/10 , A61P19/02 , A61P25/28 , A61P3/10 , A61P9/12 , A61P11/00 , A61P3/04 , C07F9/6561 , A61P25/02
Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
-
公开(公告)号：US20130059779A1
公开(公告)日：2013-03-07
申请号：US13664055
申请日：2012-10-30
Applicant: NOVARTIS AG
Inventor： David Jonathan GLASS , Mara FORNARO
CPC classification number: C07K14/475 , A61K38/30 , C07K14/65
Abstract: The invention relates to stabilized polypeptides having an IGF-1 sequence and an Ea peptide sequence, where the natural physiological cleavage of the Ea peptide from the IGF-1 is prevented.
Abstract translation: 本发明涉及具有IGF-1序列和Ea肽序列的稳定多肽，其中防止了来自IGF-1的Ea肽的天然生理切割。
-
-
Search Results
3
records
(took 0.012 seconds)
